FY2022 Q3 Financial and R&D Update
ENHERTU
DESTINY-Breast02 Study
SABCS 2022
Reconfirm favorable benefit-risk profile as a 3L treatment of HER2 positive BC
Progression-Free Survival Probability, %
100-
80
T-DXd: 62.3% (95% CI, 57.0-67.1)
TPC: 27.2% (95% CI, 20.1-34.8)
60-
40-
20-
Censor
T-DXD (n = 406)
TPC (n = 202)
PFS
T-DXd: 42.2% (95% CI, 36.5-47.8)
TPC: 13.9% (95% CI, 7.9-21.6)
ㄒㄒ
Median (95% CI), months
T-DXd
17.8 (14.3-20.8) 6.9 (5.5-8.4)
TPC
HR (95% CI): 0.3589 (0.2840-0.4535)
P<0.000001
DESTINY-Breast02 Study
Daiichi-Sankyo
Comparative study of ENHERTU ® and TPC as a 3rd line treatment
in patients with HER2 positive recurrent metastatic BC
■ENHERTUⓇ demonstrated statistically significant and
clinically meaningful improvement in PFS and OS vs. TPC
for patients with HER2+ BC previously treated with T-DM1
.
mPFS: T-DXd (17.8 months) vs. TPC (6.9 months)
.
MOS: T-DXD (39.2 months) vs. TPC (26.5 monthes)
100
Overall Survival Probability, %
60
10
40
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46
Time, months
T-DXd: 89.4% (95% CI, 85.9-92.1)
TPC: 74.7% (95% CI, 67.4-80.4)
20
0
OS
T-DXd: 65.9% (95% CI, 60.7-70.7)
TPC: 54.3% (95% CI, 46.3-61.6)
+-+-+-+--+-----+
■Overall safety profile was consistent with the established safety
of ENHERTUⓇ, with no new safety signals observed
Censor
T-DXd (n = 406)
TPC (n = 202)
I
I
Median (95% CI), months
T-DXd
TPC
39.2 (32.7-NE) 26.5 (21.0-NE)
HR (95% CI): 0.6575 (0.5023-0.8605)
P=0.0021a
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46
Time, months
Data cutoff: June 30, 2022
BC: breast cancer, Cl: confidence interval, HR: hazard ratio, NE: not estimable, mOS: median overall
survival, mPFS: median progression-free survival, OS: overall survival, PFS: progression-free survival,
SABCS: San Antonio Breast Cancer Symposium, T-DM1: trastuzumab emtansine, T-DXd: trastuzumab
deruxtecan, TPC: treatment of physician's choice
10
20View entire presentation